| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;105:230.)
© 2002 American Heart Association, Inc.
Basic Science Reports |
From the Laboratoire de Pharmacie Galénique (Y.J., N.U., M.H., P.M.), Faculté de Pharmacie, Nancy, and Service d Hématologie Biologique (M.M.-A., C.V., T.L.) CHU Brabois, Vandoeuvre-lès-Nancy, France.
Correspondence to Nathalie Ubrich PhD, Laboratoire de Pharmacie Galénique, Faculté de Pharmacie, 5, rue Albert Lebrun, BP 403, 54001 Nancy Cedex, France. E-mail ubrich{at}pharma.u-nancy.fr
Background Owing to its short half-life and lack of oral absorption, heparin has to be administered by the parenteral route. An oral heparin formulation, however, would avoid the disadvantages of parenteral injections and would consequently be highly desirable for patients. Polymeric nanoparticles (NPs) prepared with biodegradable poly-
-caprolactone (PCL) and poly(lactic-co-glycolic acid) (PLGA) and nonbiodegradable positively charged polymers (Eudragit RS and RL), used alone or in combination, were evaluated in vitro and in vivo after a single oral administration of heparin-loaded NPs in rabbits.
Methods and Results After oral administration of heparin-loaded NPs in rabbits (600 IU/kg), increases in both antifactor Xa activity and activated partial thromboplastin time (aPTT) were detected with each formulation. Moreover, the anti-Xa activity was detected for a longer period than when a heparin solution was administered intravenously. A peak concentration of 0.16±0.01 IU/mL and an average aPTT of 24 seconds (2-fold increase) were obtained 7 hours after oral dosing of Eudragit RL/PCL NPs containing heparin, exhibiting an absolute bioavailability of 23%.
Conclusions The significant increases in antifactor Xa activity and aPTT confirmed the oral absorption in rabbits of heparin released from polymeric NPs.
Key Words: heparin anticoagulants drugs nanoparticles
This article has been cited by other articles:
![]() |
H. Dou, C. J. Destache, J. R. Morehead, R. L. Mosley, M. D. Boska, J. Kingsley, S. Gorantla, L. Poluektova, J. A. Nelson, M. Chaubal, et al. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery Blood, October 15, 2006; 108(8): 2827 - 2835. [Abstract] [Full Text] [PDF] |
||||
![]() |
P R Sinnaeve and F J Van de Werf Will oral antithrombin agents replace warfarin? Heart, August 1, 2004; 90(8): 827 - 828. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |